• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.

作者信息

Stilgenbauer Stephan, Aurran Schleinitz Thérèse, Eichhorst Barbara, Lang Fabian, Offner Fritz, Rossi Jean-François, Schroyens Wilfried, Van Den Neste Eric, Ysebaert Loïc, von Wangenheim Ute, Ursula Kress Uta, Blum Petra, Zenz Thorsten

机构信息

Department of Internal Medicine III, Ulm University, 89081, Ulm, Germany.

Department of Hematology, Institute Paoli-Calmettes, Marseille, France.

出版信息

Leukemia. 2019 Oct;33(10):2531-2535. doi: 10.1038/s41375-019-0475-z. Epub 2019 May 14.

DOI:10.1038/s41375-019-0475-z
PMID:31089249
Abstract
摘要

相似文献

1
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.抗CD37抗体BI 836826用于复发/难治性慢性淋巴细胞白血病的1期首次人体试验。
Leukemia. 2019 Oct;33(10):2531-2535. doi: 10.1038/s41375-019-0475-z. Epub 2019 May 14.
2
CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.CD37 在 B 细胞来源肿瘤中的作用——不仅仅是单克隆抗体的结合点。
Int J Mol Sci. 2020 Dec 15;21(24):9531. doi: 10.3390/ijms21249531.
3
Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.idelalisib增强CD37抗体BI 836826对化疗耐药/复发起始的慢性淋巴细胞白血病细胞的细胞毒性：联合治疗的理论依据
Blood Cancer J. 2016 Nov 11;6(11):e496. doi: 10.1038/bcj.2016.106.
4
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.一项抗 CD37 单克隆抗体 BI 836826 联合伊布替尼治疗复发/难治性慢性淋巴细胞白血病患者的 Ib 期、开放性、剂量递增试验。
Invest New Drugs. 2021 Aug;39(4):1099-1105. doi: 10.1007/s10637-020-01056-4. Epub 2021 Mar 8.
5
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.含抗CD20抗体方案治疗复发或难治性慢性淋巴细胞白血病、弥漫性大B细胞淋巴瘤或滤泡性淋巴瘤患者的循证综述
Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):508-518.e14. doi: 10.1016/j.clml.2018.05.009. Epub 2018 May 23.
6
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.BI 836826（CD37 抗体）治疗复发或难治性 B 细胞非霍奇金淋巴瘤患者的 I 期剂量递增研究。
Invest New Drugs. 2020 Oct;38(5):1472-1482. doi: 10.1007/s10637-020-00916-3. Epub 2020 Mar 14.
7
Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors.
Br J Haematol. 2016 Jun;173(5):791-4. doi: 10.1111/bjh.13635. Epub 2015 Aug 14.
8
A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach.抗CD74单克隆抗体米拉妥珠单抗用于难治性慢性淋巴细胞白血病体弱患者的I-II期临床试验：基于患者的研究方法
Br J Haematol. 2018 Jul;182(1):125-128. doi: 10.1111/bjh.14726. Epub 2017 May 3.
9
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.AGS67E，一种抗CD37单甲基奥瑞他汀E抗体药物偶联物，作为B/T细胞恶性肿瘤和急性髓系白血病的潜在治疗药物：CD37在急性髓系白血病中的新作用
Mol Cancer Ther. 2015 Jul;14(7):1650-60. doi: 10.1158/1535-7163.MCT-15-0067. Epub 2015 May 1.
10
TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.TRU-016，一种用于潜在治疗B细胞恶性肿瘤的人源化抗CD37 IgG融合蛋白。
Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90.

引用本文的文献

1
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.CAR-37 T 细胞治疗复发或难治性 CD37+淋巴肿瘤患者的 1 期临床研究。
Blood. 2024 Sep 12;144(11):1153-1167. doi: 10.1182/blood.2024024104.
2
Tetraspanins predict the prognosis and characterize the tumor immune microenvironment of glioblastoma.四跨膜蛋白可预测胶质母细胞瘤的预后并描绘肿瘤免疫微环境。
Sci Rep. 2023 Aug 16;13(1):13317. doi: 10.1038/s41598-023-40425-w.
3
Current state of CAR-T therapy for T-cell malignancies.嵌合抗原受体T细胞（CAR-T）疗法治疗T细胞恶性肿瘤的现状
Ther Adv Hematol. 2022 Dec 26;13:20406207221143025. doi: 10.1177/20406207221143025. eCollection 2022.
4
Anti-CD37 α-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome.抗CD37 α-鹅膏蕈碱偶联抗体作为里氏综合征的潜在治疗武器。
Blood. 2022 Sep 29;140(13):1565-1569. doi: 10.1182/blood.2022016211.
5
Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer.四跨膜蛋白 31 的过表达促进胃癌的恶性潜能和不良预后。
Cancer Sci. 2022 Jun;113(6):1984-1998. doi: 10.1111/cas.15342. Epub 2022 Apr 1.
6
Tetraspanins as Potential Modulators of Glutamatergic Synaptic Function.四跨膜蛋白作为谷氨酸能突触功能的潜在调节因子。
Front Mol Neurosci. 2022 Jan 3;14:801882. doi: 10.3389/fnmol.2021.801882. eCollection 2021.
7
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.自然杀伤细胞在慢性淋巴细胞白血病中的作用及其治疗意义。
Int J Mol Sci. 2021 Jun 22;22(13):6665. doi: 10.3390/ijms22136665.
8
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.一项抗 CD37 单克隆抗体 BI 836826 联合伊布替尼治疗复发/难治性慢性淋巴细胞白血病患者的 Ib 期、开放性、剂量递增试验。
Invest New Drugs. 2021 Aug;39(4):1099-1105. doi: 10.1007/s10637-020-01056-4. Epub 2021 Mar 8.
9
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.一项评估抗 CD37 单克隆抗体 BI 836826 联合吉西他滨和奥沙利铂治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 Ib 期、开放性、剂量递增临床试验。
Invest New Drugs. 2021 Aug;39(4):1028-1035. doi: 10.1007/s10637-020-01054-6. Epub 2021 Feb 1.
10
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中的免疫功能紊乱及基于免疫的治疗干预。
Front Immunol. 2020 Nov 18;11:594556. doi: 10.3389/fimmu.2020.594556. eCollection 2020.